Dr. Guy Werlen is a Research Associate Professor at Rutgers Univ.-Robert Wood Johnson Medical School. He obtained his M.S and Ph.D. from the Univ. of Geneva, Switzerland. He was a post-doctoral fellow in the lab of Michael Karin at UC San Diego, where he identified new targets for T-cell immunosuppression. He was a member of the Basel Inst. of Immunology and was a Research Scientist at the Univ. Hospital Basel, Switzerland where he studied early T-cell development. His current work focuses on thymocyte development and T-cell signaling and metabolism. The goal of his research is to develop more effective immunotherapy for cancer and autoimmunity.